About Hemanext

Hemanext ONE is an FDA-authorized system that mitigates red blood cell storage lesion through hypoxic storage. This technology preserves RBC quality and functionality, aiming to improve therapeutic outcomes for transfusion recipients.

<problem> The storage of red blood cells (RBCs) leads to a phenomenon known as storage lesion, which degrades their quality and reduces their therapeutic efficacy. This degradation can negatively impact patient outcomes and the overall value of blood transfusions within the healthcare system. </problem> <solution> Hemanext ONE is an FDA-authorized processing and storage technology designed to mitigate the RBC storage lesion. By employing a hypoxic storage methodology, the system aims to preserve RBC quality, functionality, and viability throughout the storage period. This innovation seeks to enhance the therapeutic impact of transfused blood, thereby improving patient care and optimizing the utilization of blood products. The technology is intended to set a new standard of care for patients requiring blood transfusions. </solution> <features> - FDA-authorized processing and storage system for red blood cells (RBCs). - Technology specifically designed to mitigate the RBC storage lesion. - Utilizes hypoxic storage conditions to preserve RBC quality and viability. - Aims to enhance the functional capacity of stored RBCs. - Supports the optimization of therapeutic outcomes for transfusion recipients. - Developed to improve the overall value of blood products in healthcare. </features> <target_audience> The primary customers are healthcare providers, blood banks, and transfusion medicine professionals who manage and utilize blood products for patient care. </target_audience> <revenue_model> Revenue is generated through the sale and distribution of the Hemanext ONE system and associated consumables. Specific pricing details are available upon inquiry. </revenue_model>

What does Hemanext do?

Where is Hemanext located?

Hemanext is based in Lexington, United States.

How much funding has Hemanext raised?

Hemanext has raised 2900000.

Location

Lexington, United States

Funding

2900000

Employees

37 employees

Major Investors

National Institutes of Health

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Hemanext

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

hemanext.com 5K+

Crunchbase

Lexington, United States

Funding

Estimated Funding

$2M+

Major Investors

National Institutes of Health

Team (30+)

No team information available.

Company Description

Problem

The storage of red blood cells (RBCs) leads to a phenomenon known as storage lesion, which degrades their quality and reduces their therapeutic efficacy. This degradation can negatively impact patient outcomes and the overall value of blood transfusions within the healthcare system.

Solution

Hemanext ONE is an FDA-authorized processing and storage technology designed to mitigate the RBC storage lesion. By employing a hypoxic storage methodology, the system aims to preserve RBC quality, functionality, and viability throughout the storage period. This innovation seeks to enhance the therapeutic impact of transfused blood, thereby improving patient care and optimizing the utilization of blood products. The technology is intended to set a new standard of care for patients requiring blood transfusions.

Features

FDA-authorized processing and storage system for red blood cells (RBCs).

Technology specifically designed to mitigate the RBC storage lesion.

Utilizes hypoxic storage conditions to preserve RBC quality and viability.

Aims to enhance the functional capacity of stored RBCs.

Supports the optimization of therapeutic outcomes for transfusion recipients.

Developed to improve the overall value of blood products in healthcare.

Target Audience

The primary customers are healthcare providers, blood banks, and transfusion medicine professionals who manage and utilize blood products for patient care.

Revenue Model

Revenue is generated through the sale and distribution of the Hemanext ONE system and associated consumables. Specific pricing details are available upon inquiry.